Wire · operational-macro
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 October 2026 · Fusion42 review
The European Commission has approved the perioperative use of pembrolizumab plus enfortumab vedotin for all adult patients with muscle-invasive bladder cancer (MIBC) eligible for cystectomy, extending treatment beyond cisplatin-ineligible patients. This approval is based on phase 3 trial results showing significant improvements in event-free survival, overall survival, and pathologic complete response compared to standard neoadjuvant gemcitabine-cisplatin chemotherapy.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a broader market for chemo-free perioperative treatment in muscle-invasive bladder cancer across Europe as regulatory approval now includes all eligible patients, not just cisplatin-ineligible ones. Competitive pressure will rise to offer this new standard ahead of surgery.
◆ Coverage
1 source · 22 Oct 2026
◆ Related on Wire
◆ Topics